Transglutaminase fluorogenic Activity Assay

Transglutaminase Assay Kit, fluorescent

Casein, Dansylcadaverine

1 Kit 300 € available

Art. No. T036
Description Transglutaminase Activity Assay Kit
Assay principle Transglutaminases catalyze acyl transfer reactions from glutamine residues in proteins or peptides to primary amines. The transglutaminase-catayzed covalent coupling of monodansylcadaverine into N,N-dimethylcasein produces a shift in intensity and wavelength of fluorescence of the dansyl group. The transglutaminase activity can be monitored online by measurement of the fluorescence (excitation wavelength 332 nm; emission wavelength 500 nm). The relative transglutaminase activity is shown by increase of fluorescence intensity over time.
Reagents in the kit (1) SUBSTRATE REAGENT: 2 x 0,185 mg monodansylcadaverine
(2) BUFFER REAGENT: 2 x 20 ml lyophilized TRIS buffer pH 8,0 containing calcium chloride, sodium chloride, N,N-dimethylcasein, glutathione.
Equipment The Fluorescent Transglutaminase Assay can be used in standard fluorescence spectrophotometers. Refer to the instructions of the manufacturer.
Intended use Determination of transglutaminase activity (hTG1, hTG2, hTG6).
Reference(s) Lorand et al., Anal. Biochem. 1971, 44:221-31
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy